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Abstract
Recent studies have shown that low serum 25-hydroxyvitamin D (25[OH]D) level is a risk factor
for preeclampsia. The clinical significance of in vitro findings that vitamin D regulates vascular
endothelial growth factor production is unclear. We sought to determine whether there is an
association between midgestation serum 25(OH)D levels and angiogenic factor activity and to
compare their predictive value for the development of severe preeclampsia. We conducted a
nested case-control study of women with severe preeclampsia (n=41) versus women with
uncomplicated term birth (n=123) who had second trimester genetic screening (15–20 weeks).
Using banked frozen serum, we measured levels of 25(OH)D, vascular endothelial growth factor,
soluble fms-like tyrosine kinase 1, and placental growth factor and compared their correlations
and predictive values. We found no correlation between serum 25(OH)D and angiogenic factors
levels. 25(OH)D alone was comparable to vascular endothelial growth factor and soluble fms-like
tyrosine kinase 1/placental growth factor ratio as a predictive marker for severe preeclampsia. A
composite of both 25(OH)D level and soluble fms-like tyrosine kinase 1/placental growth factor
ratio was more predictive than either alone (area under curve: 0.83 versus 0.74 and 0.67,
respectively). In conclusion, combining midpregnancy 25(OH)D level with soluble fms-like
tyrosine kinase 1/placental growth factor ratio provides a better prediction for the development of
severe preeclampsia.
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Preeclampsia occurs in 2% to 5% of pregnancies and is a major cause of perinatal and
maternal morbidity and mortality.1,2 Furthermore, women with preeclampsia are at
increased risk for long-term cardiovascular complications, such as chronic hypertension,
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later in life.3 Early identification of women at risk is essential for the development of
preventive measures.
Although several theories regarding the pathogenesis of preeclampsia have emerged,4,5 few
early predictors have been identified. For example, low plasma vascular endothelial growth
factor (VEGF) in the first trimester of pregnancy is a predictive marker for preeclampsia.6,7
Increased mRNA concentrations of VEGF receptor 1, also known as soluble fms-like
tyrosine kinase 1 (sFLT-1), and decreased concentrations of placental growth factor (PlGF)
are present in women diagnosed with preeclampsia.6 – 8 In addition, sFLT-1/PlGF ratio is
increased in women who subsequently develop preeclampsia.9 These angiogenic factors
may play an important role in the pathogenesis of atherosclerosis and have a wide range of
activity depending on genotype and phenotypic factors.10
We reported recently that low midgestation serum 25-hydroxyvitamin D (25[OH]D) is a risk
factor for severe preeclampsia.11 Its active form, 1,25-dihydroxyvitamin D(3) (1,25[OH]
[2]D[3]), stimulates VEGF expression in smooth muscle cells through a vitamin D response
element in the VEGF promoter.12 We hypothesized that low serum 25(OH)D may be
associated with diminished VEGF production, leading to preeclampsia.
Our study had 2 objectives, to determine whether there is an association between early
second trimester maternal serum 25(OH)D level and angiogenic factor activity and to
compare the predictive value of serum 25(OH)D level alone versus in combination with
angiogenic factor levels, for the later development of severe preeclampsia.
Methods
Study Design
We conducted a nested, case-control study in a cohort of 3992 women (Figure 1). All of the
women who had previously given blood for routine genetic multiple marker screening and
subsequently delivered at the University of North Carolina-Chapel Hill between January
2004 and November 2008 were eligible. All pregnant women, regardless of risk status or
payer status, are offered this screening as part of routine prenatal care. Nonfasting blood
samples were collected for routine genetic multiple marker screening between 15 and 20
weeks gestation, and serum aliquots were barcoded and frozen at −70°C. Maternal
demographic and medical data were chart abstracted. This study was approved by the
University of North Carolina at Chapel Hill Institutional Review Board before data
collection, and permission was obtained to use banked serum from these women for research
purposes.
Severe preeclampsia was defined as a systolic blood pressure of ≥160 mm Hg and/or a
diastolic blood pressure of ≥110 mm Hg, recorded on ≥2 occasions 6 hours apart, plus
proteinuria (≥300 mg in a 24-hour collection or 1+ on a urine dipstick) or a systolic blood
pressure of ≥140 mm Hg and/or a diastolic blood pressure of ≥90 mm Hg, recorded on ≥2
occasions 6 hours apart plus 5 g of proteinuria in a 24-hour period. We further classified
cases of preeclampsia as severe in the setting of pulmonary edema, seizures, oliguria (<500
mL/24 hours), elevated liver enzymes accompanied by right upper quadrant pain,
thrombocytopenia (<100 000/mm3), or persistent cerebral symptoms, such as headache or
blurry vision.13 Healthy women with term deliveries (≥37 weeks) were used as controls. We
excluded from both cases and controls women with multiple gestation, major congenital
fetal anomalies, pregestational hypertension, kidney disease, diabetes mellitus, known
thrombophilias, or any other significant preexisting chronic medical disease. All of the
patient records were reviewed by a single reviewer (A.M.B.); patients meeting the strict
definitions described above were included in the study.
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From the overall cohort of 3992 women, we identified 51 cases who met all of the inclusion
and exclusion criteria. Ten did not have an adequate volume of serum available for analysis
and, thus, were excluded. The 41 remaining cases were matched by race/ethnicity, in a 3:1
ratio, to a random, computer-generated control group of 123 healthy women delivering at
term.
Laboratory Analyses
Serum aliquots for each enrolled subject were shipped on dry ice to Massachusetts General
Hospital (Boston, MA) for serum 25(OH)D measurement by liquid chromatography-tandem
mass spectrometry.14 The method used is an isotope dilution, liquid chromatography-tandem
mass spectrometry assay optimized in the Massachusetts General Hospital laboratory based
on published procedures.15 The limit of detection is 5.0 nmol for vitamin D2 and 7.5 nmol
for vitamin D3. The between-run coefficient of variation for quality control serum
containing a total vitamin D concentration of 57 nmol is 7.5%.
A second aliquot was transported to the University of North Carolina Department of
Biochemistry and Biophysics for angiogenic factor analysis. VEGF, sFLT-1, and PlGF
levels were assessed using ELISA, (R&D Systems, Minneapolis, MN) on undiluted single
serum samples. Optical density was read on a VersaMax spectrophotometric plate reader at
450 nm, with λ correction at 570 nm. For sFLT-1 and PlGF assays, all of the samples were
within the detectable limits of the assay, 4 to 3600 pg/mL and 7 to 800 pg/mL, respectively.
The detectable limits for VEGF were 0.02 to 1200.00 pg/mL. Fourteen samples, 6 controls
and 8 cases, fell below the minimum detection limit of VEGF. The interassay coefficients of
variation of sFLT-1, PlGF, and VEGF are 8%, 4%, and 5%, respectively, consistent with
other reported coefficients of variation for the assays.16
Statistical Analysis
Maternal demographic and medical characteristics were compared between cases and
controls using Fisher exact test for categorical variables and Wilcoxon-Mann-Whitney test
for continuous variables. Spearman correlations were calculated to determine whether
VEGF, sFLT-1, PlGF, or sFLT-1/PlGF ratio were individually related to 25(OH)D. Logistic
regression was used to calculate unadjusted estimated odds ratios of each predictor
separately. To examine the best combination of analytes that predicted severe preeclampsia,
logistic regression with backward selection was used, adjusting for age, body mass index
(BMI), parity, season of blood draw, and gestational age at blood draw. For the backward
selection procedure, the level of significance used was 0.05; that is, if a predictor had a P
value >0.05, it was removed from the model. Receiver operator characteristic curves and
their corresponding areas under the curve were generated to graphically compare the
predictive abilities of logistic models. A 2-sided P<0.05 was considered statistically
significant. All of the data analyses were carried out in SAS (version 9.2, SAS Institute,
Cary, NC) and R (version 2.10.1, R Foundation for Statistical Computing, Vienna, Austria).
Results
We successfully measured 25(OH)D, VEGF, and PlGF levels from the 164 samples. To
eliminate the influence of very extreme observations, 2 outlying values of VEGF >60 pg/mL
(66 and 104 pg/mL) were excluded from analysis; 95% of all of the VEGF observations
were <11 pg/mL. Three cases did not have enough serum to determine sFLT-1 levels, so
their respective controls were removed from any analysis of this variable to maintain the
matched case-control sample. Study group demographics and clinical characteristics are
presented in Table 1. The groups only differed with respect to earlier gestational age at
delivery among women with severe preeclampsia (32.6 versus 39.6 weeks; P<0.001).
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As presented in Table 1, women with severe preeclampsia had significantly lower early
pregnancy levels of 25(OH)D, VEGF, and PlGF compared with controls. sFLT-1 levels
were not significantly different between cases and controls. Women with severe
preeclampsia had higher sFLT-1/PlGF ratio than controls.
None of the angiogenic factors (VEGF, sFLT-1, PlGF, or sFLT-1/PlGF ratio) were
significantly correlated with 25(OH)D levels using the Spearman rank-based method (Table
2). The unadjusted associations between each analyte and risk of severe preeclampsia were
examined using logistic regression and are presented as odds ratio estimates in Table 3.
Individually, both 25(OH)D level and sFLT-1/PlGF ratio were significant predictors of
severe preeclampsia (P<0.001 and P<0.003, respectively).
During the model selection process, the ratio of sFLT-1/PlGF was determined to have more
predictive value than either variable alone, thus it was used in the selection procedure.
Leaving the confounders of age, BMI, parity, season of blood draw, and gestational age at
blood draw in the logistic model, 25(OH)D, VEGF, and sFLT-1/PlGF ratio were compared
in 1-, 2-, and 3- variable models for their joint predictive abilities for severe preeclampsia.
VEGF alone was the least informative of these predictors (P=0.08) and provided limited
additional information over 25(OH)D and sFLT-1/PlGF ratio. The areas under the curve,
measures of each model’s predictive ability, and the receiver operator characteristic curves
of some of the potential models are presented in Figure 2. The model containing both
25(OH)D and sFLT-1/PlGF ratio was the most parsimonious model that best predicted
severe preeclampsia. Table 4 presents the odds ratio estimates, 95% CIs and P values for this
model. After adjusting for the confounders, both 25(OH)D and sFLT-1/PlGF ratio were
highly significant independent predictors of severe preeclampsia (both P<0.001).
The odds ratio estimate of 0.95 for 25(OH)D means that each nanomole per liter increase in
25(OH)D level in the blood resulted in a 5% reduction in odds of developing severe
preeclampsia, adjusted for age, BMI, parity, season, gestational age at blood draw, and
sFLT-1/PlGF ratio. Alternatively, the odds ratio estimate for a 10-nmol/L increase in
25(OH)D level, a more clinically applicable value, is 0.62 (95% CI: 0.51–0.76), meaning
that each 10-nmol/L increase in 25(OH)D level resulted in a 38% reduction in odds of
developing severe preeclampsia, adjusted for the same variables. Similarly, the odds ratio
estimate of 1.11 for sFLT-1/PlGF ratio implied that each 1-unit increase in the ratio resulted
in an 11% increase in odds of developing severe preeclampsia, adjusted for age, BMI,
parity, season, gestational age at blood draw, and 25(OH)D level.
On further analysis, when the total study population was divided into small for gestational
age (SGA), defined as birthweight <10th percentile, and non-SGA infants, 25(OH)D and
PlGF were both significantly lower in the SGA group (P=0.006 and P=0.03, respectively).
We further examined the cases and controls separately with respect to SGA. 25(OH)D was
again significantly lower in the SGA cases compared with the non-SGA cases (P=0.01).
However, this difference was not noted in the control population.
Discussion
In the present study, we sought to determine whether there is an association between early
second trimester maternal serum 25(OH)D level and angiogenic factor activity and to
compare the predictive value of serum 25(OH)D level alone versus in combination with
angiogenic factor levels for the later development of severe preeclampsia. We found no
correlation between maternal serum 25(OH)D levels and angiogenic factors. We also found
that combining circulating midgestation levels of 25(OH)D with sFLT-1/PlGF ratio yields
better prediction of severe preeclampsia than either marker alone.
Woodham et al. Page 4













Our findings confirm and extend earlier work linking angiogenic factors with preeclampsia
risk. Several studies have provided evidence that particular alterations in angiogenic factors
are associated with preeclampsia.6 –9,17–20 However, much of this previous research
measured analytes in serum samples obtained after the development of preeclampsia and,
therefore, did not measure predictability of the disease. In addition, the relationship between
angiogenic proteins and the development of preeclampsia is complex. Previous studies that
did measure serum factors early in pregnancy usually considered single analytes when
calculating predictive values. As our study demonstrates, a single angiogenic factor may not
be the best early marker of development of severe preeclampsia.
We did not find evidence that 25(OH)D levels were associated with angiogenic factors, in
contrast with in vitro studies. Previous studies have suggested that the active hormone
1,25(OH)(2)D(3) regulates VEGF production through a vitamin D response element in the
VEGF promoter. Cardus et al21 analyzed the effects of 1,25(OH)(2)D(3) in the proliferation
of vascular smooth muscle cells. They found that 1,25(OH)(2)D(3) induces a dose-
dependent increase in vascular smooth muscle proliferation in quiescent cells and in cells
stimulated to grow. In addition, the investigators demonstrated that the effect of 1,25(OH)
(2)D(3) on vascular smooth muscle cell proliferation is mediated by an increase of the
expression of VEGF. This increase in proliferation was present both in vitro and in vivo in
animals models. In a later study, this group performed promoter transactivation analysis and
demonstrated binding of the vitamin D receptor to 2 response elements in the VEGF
promoter and subsequent VEGF promoter activation.12 The lack of association between
vitamin D and VEGF in our study may be explained by the inherent differences between in
vitro and in vivo studies, as well as animal versus human physiology.
Our study has several strengths. Maternal serum was collected in midpregnancy, before the
presence of clinical manifestations of preeclampsia, reducing the likelihood that the disease
process affected 25(OH)D and angiogenic factor levels. We excluded women with chronic
medical illnesses, such as diabetes mellitus and chronic hypertension; these diseases have
been associated with increased risk for preeclampsia and may cause preexisting alterations
in 25(OH)D and angiogenic factor activity.22 In addition, blood pressure at the time of
serum blood draw was comparable between cases and controls.
Our findings must be interpreted in the context of the study design. The sample size,
although comparable to others in the literature, is relatively small (n=41 cases). This limits
our ability to detect smaller but clinically significant differences in analyte levels between
the 2 groups. When using a case-control design, there is potential for selection bias,
particularly in the selection of controls. However, our controls were nested within a large
cohort of women who all provided serum samples as part of routine prenatal screening,
reducing selection bias. The duration of storage of the samples ranged from 2 to 6 years.
Evidence shows that long-term storage does not affect serum 25-OHD, PlGF, and sFlt-1
levels.23,24 One study showed a possible effect of storage on VEGF levels.25 Therefore,
sample storage may be a potential confounder. Our cases of preeclampsia were
heterogeneous, in that 44% of cases occurred in multiparous women. The underlying
pathophysiology of severe preeclampsia may differ in primiparous versus multiparous
women,26 and these differences may reduce our power to detect underlying mechanisms. It
is also possible that unmeasured confounding explains the apparent association between
25(OH)D deficiency, altered angiogenic factors, and severe preeclampsia. However, we
found that adjustment for some known potential confounders strengthened the observed
associations.
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In summary, contrary to our hypothesis, we found no correlation between 25(OH)D and
angiogenic factors in pregnant women. However, the combination of 25(OH)D level and
sFLT-1/PlGF ratio is a better predictor of preeclampsia in midgestation than either marker
alone. Our data suggest that 25(OH)D and angiogenic factors play independent roles in
preeclampsia pathogenesis. Preeclampsia is a significant public health concern, and
interventions aimed at reducing rates of preeclampsia are needed. Translational research
identifying potentially modifiable risk factors, such as those identified in the present study,
are essential to the success of targeting therapy. This study suggests the need for a
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Receiver operator characteristic (ROC) curve for adjusted logistic regression models.
25(OH)D indicates 25-hydroxyvitamin D; VEGF, vascular endothelial growth factor;
sFLT-1, soluble fms-like tyrosine kinase 1; PlGF, placental growth factor. Gray line
indicates no predictive ability. Area under curve is indicated in parenthesis.
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Table 1
Clinical and Demographic Characteristics of Women Who Developed Severe Preeclampsia (Cases) and Race/
Ethnicity-Matched Women Who Did Not (Controls)
Variables Severe Preeclampsia (n = 41) Controls (n = 123) P
Age, y* 29 (25–34) 29 (25–33) 0.79
Race/ethnicity, n (%) —
 White 12 (29) 36 (29)
 Black 16 (39) 48 (39)
 Hispanic 11 (27) 33 (27)
 Asian 2 (5) 6 (5)
Multiparous, n (%) 18 (44) 62 (50) 0.59
Body mass index* 30 (28–34) 30 (27–36) 0.89
Gestational age at serum collection, wk* 17.1 (16.1–18.9) 17.4 (16.4–18.3) 0.98
SBP at time of serum collection 119 (109–128) 124 (111–129) 0.49
DBP at time of serum collection 72 (65–80) 70 (61–81) 0.33
Gestational age at delivery, wk* 32.6 (30.4–34.7) 39.6 (39–40.6) <0.0001
Season of blood draw, % (n) 0.42
 Winter 12 (29) 25 (20)
 Spring 11 (27) 49 (40)
 Summer 10 (24) 29 (24)
 Fall 8 (20) 20 (16)
25(OH)D, nmol/L* 75 (53–107) 107 (90–121) <0.0001
VEGF, pg/mL* 1.9 (0.4–3.2) 3.2 (1.7–4.6) 0.0007
sFLT-1, pg/mL*† 1158 (763–1837) 1129 (819–1413) 0.46
PlGF, pg/mL* 84 (54–130) 99 (73–158) 0.03
sFLT-1/PlGF ratio*† 15.3 (8.4–27.3) 10.3 (6.4–15.9) 0.02
SBP indicates systolic blood pressure; DBP, diastolic blood pressure; 25(OH)D, 25-hydroxyvitamin D; VEGF, vascular endothelial growth factor;
sFLT-1, soluble fms-like tyrosine kinase-1; PlGF, placental growth factor. Wilcoxon-Mann-Whitney test was used for continuous variables and
Fisher exact test for categorical variables.
*
Values are median (interquartile range).
†
Because 3 cases had insufficient blood to determine sFLT-1, their matched controls were removed from any analysis pertaining to sFLT-1. Thus,
the sample sizes here are 114 for the controls and 38 for the cases.
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Table 2
Spearman Correlations of 25(OH)D With Angiogenic Factors




sFLT-1/PlGF ratio 0.134 0.10
25(OH)D indicates 25-hydroxyvitamin D; VEGF, vascular endothelial growth factor; sFLT-1, soluble fms-like tyrosine kinase-1; PlGF, placental
growth factor.
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Table 3
Unadjusted Logistic Regression Model of Each Analyte as a Predictor of Severe Preeclampsia
Analyte Odds Ratio 95% CI P
25(OH)D, nmol/L 0.97 0.96 – 0.98 <0.0001
sFLT-1/PlGF ratio 1.06 1.02–1.11 0.003
VEGF, pg/mL 0.86 0.73–1.02 0.08
25(OH)D indicates 25-hydroxyvitamin D; VEGF, vascular endothelial growth factor; sFLT-1, soluble fms-like tyrosine kinase-1; PlGF, placental
growth factor.
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Table 4
Multivariable Logistic Regression Model of 25(OH)D Level and sFLT-1/PlGF Ratio as Independent
Predictors of Severe Preeclampsia
Effect Odds Ratio Estimate 95% CI P
25(OH)D, nmol/L 0.95 0.94 – 0.97 <0.0001
sFLT-1/PlGF ratio 1.11 1.05–1.18 0.0003
Age, y 1.02 0.94–1.11 0.62
BMI, kg/m2 0.96 0.90–1.03 0.23
Parity* 0.56 0.22–1.38 0.20
Gestational age at blood draw, wk 1.01 0.76–1.34 0.93
Spring* 0.73 0.20–2.67 0.63
Summer* 1.30 0.35–4.92 0.70
Fall* 2.32 0.55–9.86 0.26
25(OH)D indicates 25-hydroxyvitamin D; sFLT-1, soluble fms-like tyrosine kinase-1; PlGF, placental growth factor; BMI, body mass index.
*
The reference groups for parity and season of blood draw are primigravida and winter, respectively.
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